TP53 and neoplasm: Tumor cell‐derived GAS5 can activate type I interferon signaling through the MYBBP1A–p53/IRF1 axis, promoting immune cell infiltration and potentially being associated with the efficacy of immunotherapy, thus inhibiting the progression of NSCLC122 (Figures 3G and 5A).